Dehydroepiandrosterone increases β-cell mass and improves the glucose-induced insulin secretion by pancreatic islets from aged rats  by Medina, Mayrin C. et al.
FEBS Letters 580 (2006) 285–290Dehydroepiandrosterone increases b-cell mass and improves the
glucose-induced insulin secretion by pancreatic islets from aged rats
Mayrin C. Medinaa, Lı´lian C. Souzaa, Luciana C. Caperutoa, Gabriel F. Anheˆa,
Ange´lica M. Amansoa, Vicente P.A. Teixeirac, Silvana Bordina, Aˆngelo R. Carpinellia,
Luiz R.G. Brittoa, Renato L. Barbierib, Maria I. Borellab, Carla R.O. Carvalhoa,*
a Department of Physiology and Biophysics, ICB, USP, Sa˜o Paulo, SP, CEP05389-970, Brazil
b Department of Cell Biology and Development, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil
c Department of General Pathology, College of Medicine of the Triangulo Mineiro, Uberaba, MG, Brazil
Received 24 October 2005; revised 27 November 2005; accepted 5 December 2005
Available online 19 December 2005
Edited by Robert BaroukiAbstract The eﬀect of dehydroepiandrosterone (DHEA) on
pancreatic islet function of aged rats, an animal model with
impaired glucose-induced insulin secretion, was investigated.
The following parameters were examined: morphological analy-
sis of endocrine pancreata by immunohistochemistry; protein lev-
els of insulin receptor, IRS-1, IRS-2, PI 3-kinase, Akt-1, and
Akt-2; and static insulin secretion in isolated pancreatic islets.
Pancreatic islets from DHEA-treated rats showed an increased
b-cell mass accompanied by increased Akt-1 protein level but
reduced IR, IRS-1, and IRS-2 protein levels and enhanced glu-
cose-stimulated insulin secretion. The present results suggest
that DHEA may be a promising drug to prevent diabetes during
aging.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Type 2 diabetes is a metabolic disease whose prevalence
among 60–74 year old Americans is over 20%. Several factors
contribute for the impaired glucose tolerance that occurs dur-
ing aging. These factors include decreased physical activity,
increased adiposity, and insulin secretory defects. In fact, im-
paired insulin secretion has been consistently demonstrated
to occur during aging [1].
Evidence exists that the insulin receptor (IR), and its main
substrates, insulin receptor substrate IRS-1 and IRS-2 are
involved in the eﬀect of insulin and insulin-like growth fac-
tor-1 IGF-1 on growth and insulin secretion in pancreatic islets
[2–4]. IRS-1 may participate in the islet response to the auto-
crine eﬀect of insulin and to glucose-induced Ca+2-dependentAbbreviations: Akt, protein kinase B, homologous to v-AKT; Beta-
IRKO, b-cell speciﬁc insulin receptor knockout mice; DHEA, dehy-
droepiandrosterone; IR, insulin receptor; IRS, insulin receptor
substrate; PI 3-kinase, phosphoinositide 3-kinase; PPARa, peroxisome
proliferator-activated receptor a
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doi:10.1016/j.febslet.2005.12.014insulin secretion [1,4]. IRS-2 plays an important role in IGF-
1 stimulation of pancreatic islet growth during late embryogen-
esis, early postnatal life and during adult life [3,5–7].
The production of dehydroepiandrosterone (DHEA) by
adrenal glands is markedly decreased during aging [8].
Administration of DHEA to rats and mice reduces visceral
adipose tissue accumulation, and has a protective eﬀect
against insulin resistance that occurs with aging. DHEA also
has been described to enhance insulin release and protect
pancreatic islets from the cytotoxicity eﬀects of interleukin-
1b and streptozotocin [9–20]. However, the mechanisms
underlying the eﬀects of DHEA on insulin release and pan-
creatic islet survival are not completed understood. In the
present study, the eﬀect of one single dose of DHEA on
pancreatic islets from aged rats was investigated. DHEA
treatment improved glucose-induced insulin secretion in pan-
creatic islets that was accompanied by enlargement of b-cell
mass. An increase of Akt-1 and a reduction in IR, IRS-1,
and IRS-2 protein levels were also observed.2. Research design and methods
2.1. Animals
One year-old male Wistar rats were obtained from the Animal
Breeding Center of the Institute of Biomedical Sciences, University
of Sao Paulo. The rats were provided with standard rodent chow
and water ad libitum. DHEA was diluted in mineral oil one week be-
fore the experiment and subcutaneously injected (10 mg/kg body
weight). The control group received equal volume of vehicle. The Ani-
mal Experimental Committee of the Institute de Biomedical Sciences,
University of Sao Paulo, guaranteed approval of the ethical aspects.
2.2. Material
Reagents for SDS–PAGE and immunoblotting were obtained from
Bio-Rad (Richmond, CA). Human biosynthetic DHEA, Tris, aproti-
nin, dithiotreitol, Triton X-100, glycerol, Tween 20, and bovine serum
albumin (BSA, fraction V) were obtained from Sigma (St. Louis, MO).
Nitrocellulose (0.45 lm) and enhanced chemiluminescence kit were
purchased from Pharmacia (Uppsala, Sweden). Anti-PI 3-kinase
(p85) antibody was purchased from Upstate Biotechnology (Lake Pla-
cid, NY). Antibodies against IRS-1, IRS-2, insulin receptor, Akt-1,
Akt-2, and insulin were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Biotinylated goat anti-rabbit antibody and avi-
din–biotin peroxidase were obtained from Vector Laboratories (Bur-
lingame, CA). Rat insulin standards and anti-rat insulin antibody
were a gift from Dr. Leclercq-Meyer, Universite´ Libre de Bruxelles,
Belgium.blished by Elsevier B.V. All rights reserved.
Table 1
Body weight and serum levels of DHEA and insulin of control and
DHEA-treated old rats
Groups Body weight (g) DHEA (ng/ml) Insulin (lU/mL)
Control 364 ± 9 (18) 0.500 ± 0.002 (4) 60 ± 4 (5)
DHEA 368 ± 8 (17) 12.6 ± 4.0a (5) 68 ± 5 (5)
The data are presented as means ± S.E.M. and the number of animals
is given in between parentheses.
aSigniﬁcant diﬀerences for P < 0.05.
Table 2
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The animals were deeply anesthetized with ketamine (5 mg/100 g
body wt i.m.) and xylazine (1 mg/100 g body wt i.m.) and perfused
through the heart with 0.9% PBS and 4% paraformaldehyde in
0.1 mol/L phosphate buﬀer. The pancreata were excised and
dissected free from surrounding tissues and ﬁxed by immersion in
4% formaldehyde–PBS solution for 4–6 h and transferred to a
30% sucrose solution in PBS for cryoprotection. Frozen pancreata
sections (20-lm) were cut on a cryostat and mounted on gelatin-
coated slides. The pancreata sections were counterstained with
hematoxylin–eosin for morphometric analysis. The islet area
morphometry was analyzed by using the NIH Image J program
(developed at the US National Institutes of Health and available
on the Internet at http://rsb.info.nih.gov/nih-image/). Hydrated
5-lm sections of paraformaldehyde-ﬁxed and paraﬃn-embedded tis-
sue were stained by the avidin–biotin complex (ABC) method. The
pancreas sections were incubated with 0.3% hydrogen peroxidase
in methanol for 30 min to block endogenous peroxidase activity.
After incubation, the sections were washed three times (5 min each)
in 0.1 mol/L phosphate buﬀer (PB) (pH 7.4). The pancreas sections
were incubated with rabbit anti-insulin antibody diluted 1:1000 at
room temperature for 12 h. The preparation was then incubated
with biotinylated goat anti-rabbit antibody diluted 1:200 in 0.1
mol/L PB containing 0.3% Triton X-100 for 2 h at room tempera-
ture, followed by 2 h incubation with ready to use avidin–biotin
peroxidase. The resulting immunocomplexes were detected with
diaminobenzidine.
2.4. Isolation of pancreatic islets
The islets were isolated by collagenase digestion of the pancreata
following the method described by Lacy and Kostianovsky [21].
Brieﬂy, the pancreas was inﬂated with a Hanks solution containing
0.7–0.9 g/L collagenase, excised and then maintained at 37 C for
20 min. The digested tissue was harvested and the islets were hand-
picked. A Krebs–Henseleit buﬀer containing 115 mM NaCl, 5 mM
KCl, 24 mM NaHCO3, 1 mM CaCl2 and 1 mM MgCl2 was used for
isolation and pooling the islets.
2.5. Immunoblotting
Batches of 300 islets from each group were homogenized by sonica-
tion (90 s) in 80 lL extraction buﬀer (100 mM Trizma, 1% SDS,
100 mM sodium pyrophosphate, 100 mM sodium ﬂuoride, 10 mM
EDTA and 10 mM sodium vanadate), and boiled for 5 min. The ex-
tracts were then centrifuged at 12000 rpm at 4 C for 20 min to remove
insoluble material. Protein determination in the supernatants was per-
formed by the Bradford dye method using the Bio-Rad reagent (Bio-
Rad Laboratories, Hercules, CA).
The proteins were treated with Laemmli sample buﬀer containing
dithiotreitol and boiled for 5 min before loading onto 8%
SDS–PAGE in a Bio-Rad miniature slab gel apparatus. Similar
sized aliquots (60–80 lg) were subjected to SDS–PAGE. Electro-
transfer of proteins from the gel to nitrocellulose was performed
for 1 h at 120 V (constant) in a Bio-Rad miniature transfer appara-
tus. Nonspeciﬁc protein binding to the nitrocellulose was reduced by
preincubation for 1 h at 22 C in blocking buﬀer (5% nonfat dry
milk, 10 mM Tris, 150 mM NaCl, and 0.02% Tween 20). The nitro-
cellulose membranes were incubated overnight at 8 C with antibod-
ies against insulin receptor b-subunit, IRS-1, IRS-2, p85 subunit of
PI3-kinase, Akt-1, and Akt-2 diluted in blocking buﬀer added with
3% nonfat dry milk, and then washed for 30 min in blocking buﬀer
without milk. The blots were subsequently incubated with peroxi-
dase-conjugated secondary antibody for 1 h, and processed for
enhanced chemiluminescence to visualize the immunoreactive bands.
Band intensities were quantiﬁed by optical densitometry (Scion
Image-Release Beta 3b, NIH, USA) of the developed autoradio-
graphs.Insulin content and pancreatic islet area
Groups Insulin (mU/islet) Islet area (lm2)
Control 3.6 ± 0.2 (100) 9996 ± 907 (25)
DHEA 4.7 ± 0.6 (180) 15325 ± 1300a (25)
The data are represented as the means ± S.E.M. of the number of islets
shown between parentheses.
aSigniﬁcant diﬀerences for P < 0.05.2.6. Glucose-stimulated insulin secretion assay
Incubations of ﬁve islets were carried out at 37 C for 60 min in
0.5 ml Krebs–Henseleit buﬀer and 0.2% albumin in the presence of
glucose. The following concentrations of glucose were used 5.6, 8.3,
11.1, and 16.7 mM and equilibrated with a mixture of O2 (95%) and
CO2 (5%). At the end of the incubation period, insulin was measured
by RIA [22].2.7. Insulin content determination
Insulin content of ﬁve islets was determined in quadruplicate from
control and DHEA-treated rats. Islets were made soluble in ethanol
at 70% plus 0.2 N HCl and then sonicated for cell disruption. Insulin
concentration was determined by RIA.
2.8. Statistical analysis
Experiments were always performed with both the control and
DHEA-treated groups in parallel. The means were statistically ana-
lyzed by unpaired Students t-test or one-way ANOVA, with Tukey
post hoc testing for individual diﬀerences between groups. The level
of signiﬁcance was set at P < 0.05.3. Results
3.1. Body weight, serum DHEA and insulin levels
Body weight, serum DHEA, and insulin levels of control and
DHEA-treated rats at the seventh day after the subcutaneous
injection of the hormone are shown in Table 1. There was no
change of body weight and insulin blood levels by DHEA
treatment. On the other hand, the injection of one single dose
of DHEA resulted in a 24-fold increase of serum DHEA levels.
3.2. Morphologic analysis of the islets
At the seventh day of DHEA injection, the area of islets
from treated rats was markedly increased in comparison to
control rats (control: 9996 ± 907 vs. DHEA: 15325 ± 1300
lm2, P < 0.01) (Table 2) in pancreata sections counterstained
with hematoxylin–eosin (Figs. 1A and B). In order to investi-
gate if the augment in the islet area was due to an increase
in b-cell mass, immunohistochemical analysis of pancreata
fragments was carried out. Marked staining for insulin was ob-
served in the central pancreatic islet cells (Fig. 1C and D). The
morphological change induced by DHEA treatment was asso-
ciated to an increase in the b-cells mass.
3.3. Glucose-stimulated insulin secretion and insulin content
The glucose-induced insulin secretion was analyzed in a
dose–response curve. The insulin secretion was signiﬁcantly
higher in DHEA-treated rats than in control rats at all glucose
concentrations. The glucose-induced insulin secretion followed
a S-shaped pattern, with the dose–response curve being shifted
Fig. 1. Morphology of pancreatic islets from control rats (A) and DHEA-treated old rats (B) counterstained with hematoxylin–eosin and
immunohistochemical analysis of insulin containing cells in control (C) and DHEA-treated (D) old rats. The bar corresponds to 50 lm.
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pancreatic islets from DHEA-treated rats there was a reduc-
tion in the secretory rate that was more pronounced at
16.7 mM glucose concentration. In spite of this ﬁnding, the
DHEA treatment had no impact on the insulin content of pan-
creatic islets (Table 2).
3.4. Insulin receptor, IRS-1, IRS-2, PI3-kinase and Akt protein
content
Content of these proteins was determined using speciﬁc anti-
bodies against the b-subunit of the insulin receptor, IRS-1,
IRS-2, the p-85 regulatory subunit of phosphoinositide 3-ki-5.6 8.3 11.1 16.7 5.6 8.3 11.1 16.7
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Fig. 2. Glucose stimulation of insulin secretion in islets from control
(open bar) and DHEA-treated rats (black bars). Groups of ﬁve islets
were incubated for 1 h with Krebs-bicarbonate medium containing
glucose at concentrations of 5.6, 8.3, 11.1, and 16.7 mM. The columns
represent the cumulative 60-min insulin secretion and represent the
means ± S.E.M. (ﬁve independent experiments). Distinct letters means
statistical signiﬁcance P < 0.05.nase (PI 3-kinase), Akt-1, and Akt-2. DHEA treatment re-
duced the protein levels of insulin receptor to 61 ± 11%
(Fig. 3A), IRS-1 to 74 ± 11% (Fig. 3B) and IRS-2 to
53 ± 25% (Fig. 3C) of the control group; the results are as
means ± S.E.M. of DHEA-treated rats.
Distinct from IR, IRS-1, and IRS-2 protein levels, DHEA
treatment had no eﬀect on the p85 subunit of PI 3-kinase
(Fig. 3D).
Downstream steps of PI 3-kinase activation involve protein
kinase B, homologous to v-AKT (Akt) phosphorylation/acti-
vation. Akt-1 protein content was increased to 148 ± 6%
(P < 0.05) (Fig. 3E) in pancreatic islets from DHEA-treated
rats as compared to controls, while the Akt-2 protein level re-
mained unchanged (Fig. 3F).4. Discussion
Increased abdominal obesity is well-known to be associated
with increased risk for development of insulin resistance.
Administration of DHEA to rodents and humans reduces
visceral fat accumulation and improves insulin sensitivity
[14–19]. The endocrine pancreata plays a central role to cope
suﬃcient insulin secretion with the metabolic demand. There
is a growing body of evidence indicating that b-cell mass is
‘‘plastic’’. Adjustments of b-cell growth and survival maintain
the balance between insulin release and blood glucose levels.
Type 2 diabetes arises when this response fails because of
either decreased b-cell mass and/or acquired b-cell secretory
dysfunction.
Here we demonstrated that one single dose of DHEA to ob-
ese aged rats induces morphological changes in endocrine pan-
creata. There was an increase of the islet area due to augment
in b-cell mass. These morphological changes were followed by
Fig. 3. Representative immunoblots showing the protein level of the
insulin receptor b-subunit (A), IRS-1 (B), IRS-2 (C), PI3K p85-subunit
(D), Akt1 (E), and Akt2 (F) in isolated pancreatic islets from rats
treated with the single DHEA dose (black bar) or vehicle (controls,
open bar). Brieﬂy, groups of 300 islets were isolated from old obese
rats treated or not with DHEA. The islets were homogenized in
extraction buﬀer. After centrifugation, aliquots from the supernatant
were submitted to SDS–PAGE before the typical immunoblotting with
the speciﬁc antibodies against each of the proteins. The bars represent
the relative protein levels as determined by optical densitometry.
Scanning densitometry was performed on autoradiograms from ﬁve
experiments similar to the one depicted here. The values are expressed
as the means ± S.E.M. \P < 0.05.
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increase in insulin content of isolated pancreatic islets. Capac-
itance measurements of exocytosis in mouse pancreatic islets
demonstrated that the maximum rate of capacitance increase
observed in b-cells is equivalent to 5% of total granule number
per second (for revision, see Ref. [23]). In this regard, the en-
hanced glucose-stimulated insulin secretion may be a conse-
quence of an increased kinetics of exocytosis in the DHEA
treated rats.
There are four independent mechanisms that regulate pan-
creatic b-cell mass: (1) replication, (2) size of cells, (3) neogen-
esis, and (4) apoptosis [24,25]. Each of these mechanisms
contributes in many ways and may change at diﬀerent stages
of life to maintain b-cell mass. In adults to seniors, b-cell mass
may decrease as apoptosis slightly outweighs b-cell replication
and neogenesis. The mechanism involved in this phenomenon
is not known. The insulin/IGF1/PI3K signaling pathway plays
an important role to determine the pancreatic b-cell mass and
to control b-cell function by regulating proliferation, survival,
and insulin secretion [26–32].
b-Cell speciﬁc insulin receptor knockout mice (BetaIRKO)
and Irs1/ mice show defective insulin secretion, with com-
pensatory hyperinsulinemia. However, one quarter of beta-
IRKO mice become diabetic with age, whereas Irs1/ mice
do not present diabetes phenotype [33–36]. Disruption of
Irs2 gene expression revealed an important role for IRS-2 in
the development of type 2 diabetes and lack of compensatory
b-cell hyperplasia [37]. A correlation between enhanced insulin
secretion and reduction of IRS-1 and IRS-2 protein levels in
pancreatic islets was also previously described in another
animal model of impaired glucose-induced insulin secretion,
the protein-deﬁcient rat [38]. Evidence is presented hereinthat both glucose-induced insulin secretion and pancreatic b-
cell mass may be associated in conditions of impaired insulin
eﬀect.
Overexpression of PKB/Akt in pancreatic b-cell results in
larger islets due to increase in both cell size and cell number,
with a positive correlation between islet cell mass and insulin
secretion [39,40]. In this regard, the restoration of insulin secre-
tion may occur by a decrease in insulin receptor, IRS-1, and
IRS-2 protein levels by DHEA treatment and increase in
Akt-1 protein level in pancreatic islets of old rats.
DHEA is an activator of peroxisome proliferator-activated
receptor a (PPARa) [41,42]. Activation of PPARa prevents
the development of diabetes in OLEFT rats by reducing adi-
posity, improving peripheral insulin action, and decreasing
the triglyceride content in pancreatic islets [43]. In our study,
however, there was no change in the body weight of the
rats.
Despite the fact that steroid hormones bind to speciﬁc intra-
cellular receptors, intracellular receptor for DHEA has not
been isolated yet. In contrast, a plasma membrane DHEA
receptor was identiﬁed that is functionally coupled to G-pro-
tein of Gai2,3 subtypes [44]. In this regard, another possibility
by which DHEA treatment reduced IR, IRS-1, and IRS-2 pro-
tein levels may involve the modulation of speciﬁc phosphoty-
rosine phosphatases that respond to the intracellular cAMP
levels. A third possibility is that PI3-kinase activation is under
the control of both insulin receptors and the GTP–protein-
coupled receptors [45]. Further studies are required to examine
these possibilities.
In summary, our study revealed that a single dose of DHEA
induces important changes in insulin receptor, IRS-1, IRS-2,
and Akt-1 protein levels, and also an increase in pancreatic
b-cell mass and glucose-induced insulin secretion by pancreatic
islets from old obese rats. These results reinforce the role of
insulin signaling pathway in the control of its own secretion
and pancreatic islet growth.
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